Finnrick, an independent testing programme, publishes 6 assays for Crush Research, and all 6 that it grades met its Purity focus threshold (at least 99.5% purity, no more than 35% dosage deviation). Most recent assay 30 Jul 2026.
Crush Research operates from US, registered as [object Object], listed by Finnrick as "Trading". Source: Finnrick, https://www.finnrick.com/vendors/crush-research.
Crush Research is listed as active.
Community standing: 4.4/5 on Trustpilot from 23 reviews. Ratings of anonymous sellers of unregulated products are the weakest signal on this page; the assay and grading records carry more.
| Product | Assays | Result |
|---|---|---|
| Retatrutide | 6 | 6 passed, 0 failed |
Source: Finnrick, as published 2026-08-09. Pass and fail are Finnrick's classification against its own threshold, not ours.
| Status | Active |
|---|---|
| Trustpilot | 4.4/5 from 23 reviews |
| Vendor type | Research-use supplier |
These details were read from Crush Research's own website on 2026-08-10. Pages consulted:
Crush Research is listed as active and we hold 6 Finnrick assays (6 passing, 0 failing its purity threshold). That is evidence about the batches that were tested or published, not a guarantee about the vial you receive.
Yes. Finnrick, an independent testing programme, publishes 6 assays for Crush Research, and all 6 that it grades met its Purity focus threshold (at least 99.5% purity, no more than 35% dosage deviation). Most recent assay 30 Jul 2026.
Popular peptides: Semaglutide, Tirzepatide, Retatrutide, BPC-157, CJC-1295, Ipamorelin.
Other reviewed vendors: Crystal Peptides Review, CSBIOMX Peptides Review, CX Peptide Review.